

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human LILRA4/CD85g/ILT7 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) LILRA5, rhILT2, 3, 4, 5, or 6 is observed.
<b>Source</b>	Monoclonal Mouse IgG <sub>2A</sub> Clone # 656688
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant human LILRA4/CD85g/ILT7 Glu24-Asn446 Accession # P59901
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Flow Cytometry</b>	2.5 µg/10 <sup>6</sup> cells	See Below
<b>CyTOF-ready</b>	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Sterile PBS to a final concentration of 0.5 mg/mL.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

LILRA4, also known as ILT7 and CD85g, is a 499 amino acid (aa) type I transmembrane glycoprotein that contains four Ig-like domains in its extracellular region. LILRA4 is selectively expressed on plasmacytoid dendritic cells (pDC). It binds to BST2/CD317 on bone marrow stromal cells and associates with the gamma subunit of Fc epsilon RI. This receptor complex transmits signals that inhibit the TLR-induced production of type I interferon. The LILRA4-mediated interactions between pDC and tumor cells similarly inhibit the production of proinflammatory cytokines and contribute to reduced anti-tumor immune responses. Alternate splicing of human LILRA4 generates an isoform that lacks the N-terminal 43 aa of the extracellular domain.